The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer

Introduction: Most cases of Triple Negative Breast Cancer (TNBC) have a high proliferation rate. TNBC is associated with a poor prognosis, a high recurrence rate, and a high incidence of distant metastases. The Epithelial-Mesenchymal Transition process (EMT) plays an essential role in the metastatic process. EMT markers were also more abundant in TNBC and contributed to a poorer TNBC prognosis. As an important EMT marker, the increased expression of vimentin also contributed to the increase in TNBC aggressiveness and resistance to chemotherapeutic agents. Through the mechanism of action in inh

Trial Details

NCT ID
NCT05550415
Phase
PHASE2
Sponsor
Indonesia University
Status
RECRUITING
Cancer Type
Ductal Carcinoma In Situ (DCIS) Breast Cancer
Interventions
  • Simvastatin 40mg
  • Placebo
Locations (sample)
  • Jakarta Pusat, DKI Jakarta, Indonesia|-6.1818,106.8223

Key Eligibility Criteria

  • Female patients with advanced breast cancer (locally advanced and distantly advanced) with triple-negative molecular type confirmed by biopsy and i…
  • The patient planned to receive 8 cycles of AC-T chemotherapy.
  • Patient age \> 18 years.
  • Willing to participate in research by signing informed consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ductal Carcinoma In Situ (DCIS) Breast Cancer Trials on Trialify →